8.3 Anticoagulation Management: Heparin Protocols & Citrate

Anticoagulation Management: Heparin Protocols & Citrate

When blood exits the vascular system and contacts the synthetic polymeric surfaces of the extracorporeal circuit, defensive hemostatic cascades activate instantaneously. Without effective anticoagulation, thrombotic deposition rapidly occludes hollow fibers and drip chamber filters, causing blood loss, degraded solute clearance, and premature treatment termination. Conversely, excessive systemic anticoagulation predisposes the patient to life-threatening hemorrhagic complications. The certified hemodialysis nurse must balance preventing extracorporeal clotting against mitigating patient bleeding risks.

---

Principles of Hemodialysis Anticoagulation

Circulation through foreign bloodlines triggers the intrinsic coagulation pathway and cellular activation through distinct physiological mechanisms:

Surface-Induced Contact Activation & Thrombogenesis

1. Factor XII (Hageman Factor) Activation: Contact between plasma proteins and negatively charged synthetic tubing surfaces induces a conformational change in factor XII, converting it to activated factor XIIa. This stimulates factor XI, triggering the intrinsic cascade and leading to factor X activation and thrombin (factor IIa) generation.
2. Platelet Adhesion & Shear Activation: Plasma fibrinogen adsorbs onto synthetic membrane fibers within milliseconds of blood contact. Platelet surface receptors (glycoprotein IIb/IIIa) bind to this adsorbed fibrinogen, stimulating platelet degranulation, thromboxane A₂ release, and aggregation.
3. Thrombin Generation & Fibrin Polymerization: Thrombin cleaves circulating fibrinogen into insoluble fibrin monomer strands that cross-link across the dialyzer fiber bundles and venous drip chamber mesh, forming a dense red thrombus.

Balancing Thrombosis Prevention Against Hemorrhagic Risk

Anticoagulation goals during hemodialysis are:

• Maintaining circuit patency throughout the 3- to 4-hour treatment.
• Minimizing erythrocyte trapping and documenting any circuit blood that cannot safely be returned.
• Limiting anticoagulant effect at termination so hemostasis can be achieved without excessive bleeding; a fixed number of minutes does not prove the effect has resolved.

---

Unfractionated Heparin (UFH) Administration Protocols

Unfractionated heparin remains the most widely utilized anticoagulant in maintenance hemodialysis due to its predictable pharmacokinetics, ease of bedside monitoring, short elimination half-life, and low cost.

Mechanism of Action

Heparin functions as an indirect anticoagulant. It binds reversibly to antithrombin III (AT-III) via a unique high-affinity pentasaccharide sequence. This binding accelerates AT-III's natural rate of inactivating activated clotting factors—primarily thrombin (factor IIa) and factor Xa—by more than 1,000-fold. Heparin also inhibits factors IXa, XIa, and XIIa to a lesser degree. Heparin's biological half-life ranges from 60 to 90 minutes, although it may be prolonged in patients with end-stage renal disease.

Standard Systemic Heparinization Protocol

For patients with average bleeding risk, standard systemic anticoagulation consists of two phases:

• Initial dose: The clinician selects a weight-based or fixed regimen. At 30–50 units/kg, a 70-kg example gives 2,100–3,500 units; do not equate that range with a universal 1,000–2,000-unit dose.
• Continuous Maintenance Infusion: Delivered via the machine's automated syringe infusion pump at a rate of 500 to 1,500 units/hour into the bloodline pre-dialyzer.
• Stop-time is individualized to the agent, bleeding risk, access and protocol; a fixed 30–60-minute window is not mandatory for every patient.

Low-Dose ("Tight") Heparin Protocol

The clinician may select a reduced-dose regimen for particular bleeding risks, or choose heparin-free treatment. Active bleeding requires reassessment before any systemic dose. Illustrative older low-dose protocols include the following; they are not mandatory prescriptions:

• Reduced Bolus: 500 to 1,000 units at initiation.
• Reduced Maintenance: 250 to 500 units/hour continuous infusion.
• Target Parameter: Coagulation times are maintained at modest elevations (1.2 to 1.5 times baseline) rather than full systemic therapeutic targets.

Coagulation Monitoring

ACT, aPTT or other testing may be used according to the anticoagulant and validated protocol. ACT results depend on the instrument and conditions; there is no universal 150–200-second target for every HD regimen. Assess circuit streaking, clotting, pressure and prolonged bleeding with laboratory information. UFH response and half-life vary with dose and patient factors. A clotting circuit does not automatically mean the patient needs more heparin: low flow, access dysfunction or air contact may contribute.

Performing Clotting-Time Tests

Activated clotting time (ACT) commonly uses fresh whole blood in a point-of-care cartridge or tube with a contact activator. Verify the correct test, device quality controls, specimen source and collection time. Avoid unintended heparin contamination or saline dilution. Fill and close the cartridge as labeled, test promptly within its allowed interval, and record the result in seconds with the time relative to anticoagulant administration. Clotted, delayed or incorrectly filled specimens can mislead dose decisions.

Activated partial thromboplastin time (aPTT) is a laboratory clotting assay commonly performed on plasma from a correctly filled citrate specimen. Follow the laboratory's collection, mixing and transport instructions. Underfilling or contamination can distort results. Interpret the baseline, current result and assay-specific target with the ordered protocol. A high result with bleeding and a low result with visible circuit clotting need different assessments; neither permits an unapproved dose change.

Heparin-Free Hemodialysis Protocols

When any systemic anticoagulation poses unacceptable risk, dialysis must proceed using a strictly heparin-free protocol.

Clinical Indications for Heparin Avoidance

Avoid or modify heparin when bleeding risk is unacceptable, using the prescribed alternative. Suspected HIT requires immediate avoidance of all heparin sources and urgent clinical evaluation.

• Active internal hemorrhage (gastrointestinal bleeding, retroperitoneal hematoma).
• Severe thrombocytopenia (platelet count $< 50,000/\mu\text{L}$).
• Uremic Pericarditis: Heparin administration in patients with pericardial friction rubs can convert serofibrinous pericarditis into hemorrhagic pericardial tamponade, causing acute cardiovascular collapse.
• Recent major surgery or trauma (within 48 to 72 hours), particularly intracranial, ocular, or spinal cord procedures where minor bleeding produces catastrophic deficits.
• Suspected or confirmed Heparin-Induced Thrombocytopenia (HIT).

Heparin-Free Technique

Confirm the prescribed circuit and prime with heparin-free saline. Do not add heparin to the prime when the treatment is ordered heparin-free; in suspected HIT, avoid every heparin source, including locks, flushes and coated devices when applicable. Adequate de-airing and prescribed flow reduce stasis. Saline flush frequency and volume are ordered according to patient and circuit needs, with surveillance for streaking, rising pressure and reduced clearance. No flush schedule guarantees that clotting will be prevented.

When clotting occurs, secure the circuit and assess blood-return safety according to protocol. Do not force clots into the patient or increase systemic anticoagulation without authorization. Investigate low flow, needle position, access function, contact time and visible circuit conditions. Record the treatment loss and any blood that cannot safely be returned.

Fluid Accounting in Heparin-Free Dialysis

Record all administered flushes and review the fluid goal with the patient’s perfusion and ordered plan. Eight 100-mL flushes add 800 mL; do not automatically force extra UF in an unstable patient.

---

Heparin-Induced Thrombocytopenia (HIT Type II)

Heparin-Induced Thrombocytopenia (HIT) is an immune-mediated disorder associated with significant morbidity and mortality.

Immune-Mediated Pathophysiology

HIT Type II is caused by IgG antibodies directed against complexes formed between circulating Platelet Factor 4 (PF4) (a chemokine released from platelet alpha-granules) and unfractionated or low-molecular-weight heparin. The resulting IgG-PF4-heparin immune complexes bind to Fc$\gamma$RIIa receptors on platelet surfaces. This triggers massive platelet activation, degranulation, and thrombin generation. Active platelet consumption causes thrombocytopenia, while widespread platelet micro-aggregates trigger diffuse arterial and venous thrombosis—a paradox termed "white clot syndrome."

Clinical Presentation & Diagnostic Criteria

• Thrombocytopenia: An unexplained drop in platelet count by > 50% from baseline, typically manifesting 5 to 10 days after initial heparin exposure (or within hours if the patient was exposed to heparin within the past 100 days).
• Extracorporeal Clotting: Rapid, repeated clotting of dialyzers and venous drip chambers despite escalating heparin boluses.
• Thrombotic Complications: Deep venous thrombosis, pulmonary embolism, stroke, acute myocardial infarction, limb ischemia, and vascular access thrombosis.

Immediate Management & Alternative Anticoagulation

1. Immediate Cessation of All Heparin: Discontinue all systemic heparin infusions, catheter locks (heparin-free saline or citrate locks must be substituted), and heparinized saline flushes. Never administer low-molecular-weight heparin (dalteparin, enoxaparin), as cross-reactivity exceeds 90%.
2. Transition to Direct Thrombin Inhibitors (DTIs):
   • Argatroban: A small-molecule direct thrombin inhibitor that binds reversibly to the catalytic site of free and clot-bound thrombin. Argatroban is one option for acute HIT in renal replacement therapy because hepatic clearance can be useful in kidney failure. Hepatic dysfunction and critical illness still influence dosing; ASH also lists alternatives selected by the specialist and clinical context. Dosing is adjusted to achieve a target aPTT of 1.5 to 3.0 times baseline.
   • Bivalirudin: An alternative synthetic DTI; however, because it undergoes partial renal elimination (approx. 20%), dosing must be reduced and carefully titrated in hemodialysis patients.

---

Regional Citrate Anticoagulation (RCA)

Regional citrate primarily anticoagulates the extracorporeal circuit and can reduce systemic anticoagulant exposure. Citrate that enters the patient still affects calcium and acid-base balance, so it is not free of systemic effects.

Biochemical Chelation & Local Dialyzer Anticoagulation

Trisodium citrate is infused continuously into the arterial bloodline immediately as blood exits the patient's vascular access. Citrate chelates free ionized calcium ($Ca^{2+}$), forming soluble calcium citrate complexes. Because ionized calcium is an obligatory cofactor for clotting enzyme complexes (factors IXa, Xa, and the prothrombinase complex), lowering circuit ionized calcium inhibits coagulation. Many protocols use a low circuit-ionized-calcium target, but the exact target and adjustment rules belong to the validated protocol; 0.35 mmol/L is not a universal guarantee of complete inhibition.

Post-Dialyzer Calcium Restoration & Systemic Neutrality

Citrate and calcium-citrate complexes are partially cleared across the dialyzer membrane into the dialysate effluent. The remaining citrate enters the systemic circulation, where it is metabolized by the liver, skeletal muscle, and renal cortex into bicarbonate. To prevent systemic hypocalcemia, the prescription specifies calcium delivery and monitoring. Some protocols use calcium chloride or gluconate infusion at an approved post-filter or separate site; other approaches depend on the dialysate and system. Verify the exact route and concentration. Systemic ionized calcium is measured and titrated to the protocol, not assumed normal from the presence of an infusion.

Citrate Accumulation and Calcium Ratios

Regional citrate anticoagulation requires a validated protocol with citrate delivery, calcium replacement, laboratory timing and clear escalation limits. Monitor systemic and circuit ionized calcium, total calcium, acid-base status and sodium as ordered. Citrate accumulation may cause a rising total-to-ionized calcium ratio, falling ionized calcium and increasing calcium replacement needs; a ratio above approximately 2.5 is a warning signal in the appropriate clinical context, not the sole diagnosis.

Use the same units in numerator and denominator. Convert total calcium in mg/dL to mmol/L by multiplying by approximately 0.2495 before dividing by ionized calcium in mmol/L. For total calcium 8.8 mg/dL and ionized calcium 1.1 mmol/L, total calcium is about 2.20 mmol/L and the ratio is 2.0. Dividing 8.8 directly by 1.1 would yield 8.0 and a false toxicity signal. Total calcium 12 mg/dL with ionized calcium 0.9 mmol/L yields about 3.0/0.9 = 3.33, prompting urgent protocol review.

Reduced citrate metabolism, impaired perfusion and severe illness can increase risk. Nurses must not independently change calcium or citrate rates from a ratio alone. Confirm specimen source, results and protocol instructions, notify the clinician, and evaluate the patient for symptoms and ECG changes. Citrate also affects acid-base balance; accumulation and excessive citrate delivery are different problems and require different responses.

Sources checked 2026-10-10: ASN hemodialysis emergencies; device and treatment instructions govern the individual procedure.

Methods checked 2026-10-11: Abbott ACT test, MedlinePlus PTT test, ASH HIT guidance.